NCT01268163View on ClinicalTrials.gov

The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Cancer
Interventions
DRUG

European Taxotere®

60-100 mg/m\^2 IV

DRUG

American Taxotere®

60-100 mg/m\^2 IV

DRUG

Hospira Docetaxel Injection

60-100 mg/m\^2 IV

Trial Locations (4)

Unknown

Saint Petersburg

Cambridge

Glasgow

Manchester

All Listed Sponsors
lead

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT01268163 - The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer | Biotech Hunter | Biotech Hunter